Ocrelizumab

30 trials 7 recruiting LOncology

Filter these 30 trials by condition, phase, country and more.

Open in Search →

30 Registered trials

7 Recruiting

20 Completed trials

15 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 19 Phase II: 6 Phase III/IV: 2 Phase IV: 3

Oversight events:

2 serious breaches 11 temporary halts 4 unexpected events across 7 trials

View oversight register →

Indications tested

Multiple sclerosis 13 Relapsing-remitting multiple sclerosis 10 Primary progressive multiple sclerosis 4 Secondary progressive multiple sclerosis 3 Progressive multiple sclerosis 3 Multiple sclerosis relapse 2 Clinically isolated syndrome 1 Nervous system disorder 1 Relapsing multiple sclerosis 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 14 Centre Hospitalier Universitaire De Nantes 2 Helse Bergen HF 2 Amgen Inc. 1 Amsterdam UMC 1 Amsterdam UMC Stichting 1 Antwerp University Hospital 1 Celltrion Inc. 1 CHU De Rouen 1 Fakultni Nemocnice Ostrava 1 Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S 1 Hopital Fondation Adolphe De Rothschild 1

All trials — page 2

30 total

STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended

2023-506429-13-00 Phase III 7 countries F. Hoffmann-La Roche AG
RAM-MS Ended

2024-510630-40-00 Phase III 4 countries Helse Bergen HF
A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab… Ended

2023-505975-54-00 Phase III 4 countries F. Hoffmann-La Roche AG
A Study to Evaluate B Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy - The MINORE Study Ended

2024-510974-25-00 Phase IV 2 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Phase III 14 countries F. Hoffmann-La Roche AG

Showing 25–30 of 30 trials

← All drugs A–Z